Agile Therapeutics Appoints John Hubbard, Ph.D., FCP to Its

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Agile Therapeutics Appoints John Hubbard, Ph.D., FCP to Its Board of Directors

PRINCETON, N.J., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX ) today announced that John Hubbard, Ph.D., FCP has been appointed to the Company's Board of Directors, effective November 18, 2014. Dr. Hubbard will serve on Agile's Nominating and Corporate Governance Committee.

"John's exceptional pharmaceutical experience and expertise leading global clinical trial operations and research and development programs will provide us with a valuable perspective as we advance our Phase 3 clinical trial for Twirla ® ," said Al Altomari, President and Chief Executive Officer at Agile. "We welcome John to our board and look forward to his insight and guidance as we continue to execute on our core strategies to develop innovative women's contraceptive healthcare products."

Dr. John Hubbard currently serves as Senior Vice President and Worldwide Head of Development Operations for Pfizer Inc., and is responsible for the global clinical trial operations and management of more than 450 clinical projects from Phase 1 to 4. He recently announced that he will leave Pfizer in January 2015, to pursue an executive leadership role in the healthcare services area. Dr. Hubbard has been leading pharmaceutical research and development activity for nearly thirty years and held positions of increasing responsibility in the biopharmaceutical and clinical research & development services industries. Prior to joining Pfizer in 2010, he was Group President, Clinical Research Services at ICON Clinical Research, a leading global clinical research organization, where he was responsible for the global business and operations. During his career, Dr. Hubbard has been directly responsible for drug discovery and non-clinical pharmacology, clinical pharmacology, project management, product development optimization, commercial assessment of new chemical entities, and clinical development operations. He has led several drug development teams to successful commercialization of new chemical entities and has participated at FDA meetings to support end of Phase 2 and end of Phase 3 data presentations for psychiatric, neurological, cardiovascular, and anti-infective drugs. 

He is a member of the Society of Clinical Pharmacology and Therapeutics, Drug Information Association and served on the Special Interest Advisory Committee on Project Management. He also served as Chairman of the Fellow of the American College of Clinical Pharmacology (ACCP) Public Policy Committee from 1999 to 2007. Dr. Hubbard is a Board Certified Diplomat in Applied Pharmacology and elected to Fellow of the ACCP in 1994. Dr. Hubbard received a Bachelor of Science degree in Biopsychology from the University of Santa Clara and a Doctorate from the University of Tennessee, with a research focus on the genetic basis of hypertension and autonomic dysfunction. He was a National Institute of Health Postdoctoral Fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center.

Dr. Hubbard has authored and co-authored several book chapters and published numerous articles and abstracts in the areas of biopsychology, cardiovascular and autonomic pharmacology, clinical pharmacology, and global drug development. He is a Board Member of TransCelerate Biopharma, Inc., a Business Advisory Board Member of SAFE Biopharma, and an Advisory Board Member and Fundraising Vice-chair for the Children's Brain Tumor Foundation.

About Agile

Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com .

Agile Therapeutics Investor Relations Mary Coleman (609) 683-1880

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 125

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 134

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 133

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
IIT Madras Maps 100 Brains in a Serious Science Bet

Updated Category News Views 40

A human brain turned into a navigable cellular map is not a flashy launch-day trinket. It is painstaking infrastructure, the kind that can sit quietly for years before researchers figure out what it truly unlocks. That is why the Sudha Gopalakrishnan Brain Centre mission at IIT Madras deserves a serious look rather than the usual chest-thumping over a big scientific...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 118

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 93

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 109

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
SHIFTAIon Puts Governance at Center of AI Migration

Updated Category News Views 69

Legacy code is where grand AI promises usually go to get mugged by reality. ACL Digital’s new SHIFTAIon platform is taking a sensible swing at that ugly problem: not merely generating code faster, but putting discovery, architecture decisions, testing, security checks, reviewer signoffs, and reporting into one controlled modernization process. That distinction matters....

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 194

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 103

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading

Top 5 Most Recently Viewed Articles

HERE Technologies Celebrates Sustainability Efforts in 2024 Report

Updated Category News Views 986

HERE Technologies Unveils Annual Sustainability Report for 2024 HERE Technologies, the frontrunner in location data and technology, has rolled out its fifth annual Sustainability Report, which spotlights the advances made in Environmental, Social, and Governance (ESG) initiatives. This year, the report highlights HERE's integral part in facilitating global sustainability...

Continue Reading
Rocket Lab's HASTE Launch Enhances National Defense Initiatives

Updated Category News Views 195

Rocket Lab's Successful HASTE Launch Elevates National Defense Rocket Lab Corporation (Nasdaq: RKLB) has made waves in the aerospace sector with its latest achievement, a successful launch of the HASTE mission. This mission has great importance for not only Rocket Lab as a prominent provider of launch services and space systems but also for national security. This launch,...

Continue Reading
Jabil's Stock Surge Driven by New Warrant Issuance

Updated Category News Views 197

Jabil Inc. Shares Experience a Positive Shift Jabil Inc. (NYSE: JBL) is making headlines as its stock sees an upward movement, particularly notable on a recent Friday. This surge is primarily attributed to the announcement regarding a warrant issuance to Amazon.Com, Inc. (NASDAQ: AMZN) NV Investment Holdings. This strategic move allows Amazon to potentially acquire up to...

Continue Reading
Understanding Net Asset Values for Middlefield Income PCC

Updated Category News Views 152

Exploring Net Asset Values of Middlefield Canadian Income PCC The Middlefield Canadian Income PCC holds a distinct position in the investment landscape. Its net asset value (NAV) reflects the value of the company's assets minus its liabilities, providing a clear picture of its financial health. Recent Measurements of Net Asset Value As of a recent assessment, the...

Continue Reading
Innovative Fundraising at The Folded Flag Foundation Gala

Updated Category News Views 112

A Night to Remember: The Folded Flag Foundation Gala The Folded Flag Foundation recently held its annual gala, and the community truly came together, raising an impressive $1.1 million. This significant amount will go toward supporting Gold Star families. This event has gained a reputation for honoring the legacies of America's fallen service members, making it an...

Continue Reading